Novartis' Beovu label leaves something to be desired: analysts by Eric Sagonowsky Thursday, October 10, 2019 Novartis' Beovu will be going up against entrenched rivals with a couple blemishes in its label, analysts wrote.
Novartis takes on Regeneron, Roche blockbusters with Beovu by Eric Sagonowsky Tuesday, October 8, 2019 Novartis has its next big drug approval. The FDA on Tuesday approved wet AMD drug Beovu, which will go up against Regeneron and Roche meds.
